NBIX Overview
Upcoming Projects (NBIX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (NBIX)
-
Discussing CAH (Congenital Adrenal Hyperplasia) and therapies in development, including crinecerfont and tildacerfont
Tickers: SPRB, NBIX
Executed On: Feb 13, 2024 at 04:00 PM EST -
Discussing the results of Neurocrine's CAHtalyst study with crinecerfont in Congenital adrenal hyperplasia
Ticker: NBIX
Executed On: Jan 22, 2024 at 10:00 AM EST -
Digging into the Phase 3 CAHtalyst study of Neurocrine's crinecerfont in adults for the treatment of CAH due to 21-OHD
Ticker: NBIX
Executed On: Oct 02, 2023 at 04:00 PM EDT -
A Second Look: Discussing the potential of Neurocrine Bio's recently FDA approved INGREZZA (valbenazine) for the treatment of Chorea associated with Huntington's Disease
Ticker: NBIX
Executed On: Sep 18, 2023 at 02:00 PM EDT -
Discussing the potential of Neurocrine Bio's recently FDA approved INGREZZA (valbenazine) for the treatment of Chorea associated with Huntington's Disease
Ticker: NBIX
Executed On: Sep 05, 2023 at 04:00 PM EDT -
Discussing therapies in development for Congenital Adrenal Hyperplasia (CAH) including Neurocrine Biosciences' gene therapy Crinecerfont
Ticker: NBIX
Executed On: Jul 15, 2022 at 11:00 AM EDT
Expired Projects (NBIX)
Upcoming & Overdue Catalysts (NBIX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (NBIX)
-
Phase 3 Topline data of Neurocrine's (NBIX) Elagolix in treating Uterine Fibroids expected Q1 2018
Tickers: NBIX, ABBV
Occurred on: Feb 21, 2018 -
NDA for Elagolix in treating Endometriosis anticipated in 3rd Quarter 2017
Tickers: ABBV, NBIX
Occurred on: Sep 06, 2017 -
Proof of Concept Study in Essential Tremor expected Mid-year
Ticker: NBIX
Occurred on: Aug 03, 2017 -
Neurocrine (NBIX) Expects Phase 2 T-Force GREEN Data in Q2 Evaluating Ingrezza in Pediatric Patients With Tourette Syndrome
Ticker: NBIX
Occurred on: May 23, 2017 -
Phase 1b in Congenital Adrenal Hyperplasia expected to begin 1st Half of 2017
Ticker: NBIX
Occurred on: May 09, 2017 -
FDA Approves Neurocrine's (NBIX) INGREZZA (valbenazine) New Drug Application (NDA) in Tardive Dyskinesia
Ticker: NBIX
Occurred on: Apr 11, 2017 -
Neruocrine (NBIX) Phase 3 KINECT 3 Data Evaluating Ingrezza in Tardive Dyskinesia Published in the American Journal of Psychiatry
Ticker: NBIX
Occurred on: Mar 21, 2017 -
Neurocrine Projected to file IND for CRF Antagonist Compound in 2016
Ticker: NBIX
Occurred on: Feb 14, 2017 -
Phase 2 T-Forward Data due in Early 2017 for Neurocrine's (NBIX) Ingrezza (Valbenazine) in Adults with Tourette Syndrome
Ticker: NBIX
Occurred on: Jan 17, 2017 -
Neurocrine's (NBIX) Phase 2 T-Force Green Results Evaluating Ingrezza in Adults with Tourette Syndrome due in Early 2017
Ticker: NBIX
Occurred on: Jan 17, 2017 -
Neurocrine's (NBIX) NDA Filing of Ingrezza Accepted for Priority Review in Tardive Dyskinesia
Ticker: NBIX
Occurred on: Oct 11, 2016 -
Neurocrine Biosciences Expects to File NDA for NBI-98854 (valbenazine) in 2016
Ticker: NBIX
Occurred on: Aug 29, 2016 -
Valbenazine NDA for tardive dyskinesia expected to be filed in 2016
Ticker: NBIX
Occurred on: Aug 29, 2016 -
Phase 3 data from second trial of Elagolix for Endometriosis due 1Q 2016
Ticker: NBIX
Occurred on: Feb 10, 2016
Strategic Initiatives (NBIX)
-
Neurocrine Biosciences (NBIX) and Xenon Pharmaceuticals(XENE) Announce Agreement to Develop First-in-Class Treatments for Epilepsy
Tickers: NBIX, XENE
Announcement Date: Dec 02, 2019
